MIRA Pharmaceuticals Expands Ketamir-2 IP to 10 Major Markets Ahead of Phase 2a
MIRA is trading near its 52-week low of $0.9 (11% above the low).
Summary
MIRA Pharmaceuticals has secured worldwide licensing rights for its lead drug candidate, Ketamir-2, expanding its intellectual property to 10 major global markets. This strategic move follows positive Phase 1 results for Ketamir-2 announced on May 13th and precedes its planned Phase 2a development for chemotherapy-induced peripheral neuropathy. The expanded global IP significantly enhances the drug's commercial potential and MIRA's ability to attract strategic partners, which is critical for a company that recently reaffirmed a going concern status. The company is now preparing Phase 2a protocol documentation for FDA submission.
At the time of this announcement, MIRA was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $40.9M. The 52-week trading range was $0.90 to $2.45. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: ACCESS Newswire.